First human test: how does a new drug act in damaged livers?
NCT ID NCT07401862
Summary
This is an early safety study to see how a new drug, eloralintide, is processed by the body in people with healthy livers and in people with mild, moderate, or severe liver damage. Researchers will give a single injection and then closely monitor participants for about 14 weeks to measure drug levels and check for side effects. The goal is to understand if liver function changes how the drug works, which is important for future studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATIC INSUFFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
American Research Corporation
RECRUITINGSan Antonio, Texas, 78215, United States
Contact Phone: •••-•••-••••
Contact
-
CRU Early Phase Unit
NOT_YET_RECRUITINGKistarcsa, H-2143, Hungary
Contact Phone: •••-•••-••••
Contact
-
Orlando Clinical Research Center
RECRUITINGOrlando, Florida, 32809, United States
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.